<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALOXI- palonosetron hydrochloride capsule, gelatin coated </strong><br>Eisai Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use ALOXI Capsules safely and effectively. See full prescribing information for</span><span class="Bold">ALOXI.<br><br></span><span class="Bold">ALOXI (palonosetron HCl) Capsules <br>Initial U.S. Approval: 2003</span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions (<a href="#LINK_df88ea49-b445-48ae-bae3-1e09621842e7">5.2</a>)                                             09/2014 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ALOXI Capsules, a serotonin subtype 3 (5-HT<span class="Sub">3</span>) receptor antagonist, are indicated for: </p>
<ul class="Disc"><li>Moderately emetogenic cancer chemotherapy -- prevention of acute <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses (<a href="#LINK_6332bff5-aee8-494b-8dc0-a1d7d11241e6">1.1</a>)</li></ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Adult Dosage: one 0.5 mg capsule administered approximately one hour prior to the start of chemotherapy (<a href="#LINK_f14179b3-25b4-4b01-87ec-973f7e0d0348">2.1</a>)<br>      </p>
<p class="Highlighta">ALOXI can be taken with or without food (<a href="#LINK_cd6f60c3-464c-4e4e-8acf-e606d0816744">12.3</a>) </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">0.5 mg capsule (<a href="#LINK_abff6fc2-20a6-4b2f-b135-e774b8c3eef2">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">ALOXI is contraindicated in patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any of its components (<a href="#LINK_d6471d7a-111b-48df-af25-62107057cb64">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may occur in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other 5-HT<span class="Sub">3</span> receptor antagonists (<a href="#LINK_8a5bb05b-3cd7-4b3a-a37e-e573b3f09ef5">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> has been reported with 5-HT<span class="Sub">3</span> receptor antagonists alone but particularly with concomitant use of serotonergic drugs (<a href="#LINK_df88ea49-b445-48ae-bae3-1e09621842e7">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">No adverse reactions have been reported at an incidence of ≥5 % for the 0.5 mg dose. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> are the most common adverse reactions but occur less frequently (<a href="#LINK_8f40395e-3a54-48c7-8196-61408c7b1600">6</a>) </p>
<p class="Highlighta">      <br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact EISAI at 1- 888-422-4743 or FDA at 1-800-FDA-1088 or </span><span class="Bold">www.fda.gov/medwatch.</span><br>       </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">The potential for clinically significant drug interactions with palonosetron appears to be low (<a href="#LINK_19a570b8-cdb7-42e4-8513-96942f183292">7</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Safety and effectiveness in patients below the age of 18 years have not been established (<a href="#LINK_ec23e3d5-187d-45d1-b8e1-6be6cad6f7c1">8.4</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Prevention of
Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended
Dosing</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical
Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Renal
Impairment</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Hepatic
Impairment</a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Race</a></h2>
<h2><a href="#section-8.9" class="toc">8.9 Gender</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 

Carciogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_4c484783-2f41-4aff-bb25-60e1b183742c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6332bff5-aee8-494b-8dc0-a1d7d11241e6"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Prevention of
Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">ALOXI Capsules are indicated for:</p>
<ul class="Disc"><li>Moderately emetogenic cancer chemotherapy - prevention of acute <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_1803439c-d626-4421-ae9c-cd667a0cf47e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f14179b3-25b4-4b01-87ec-973f7e0d0348"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended
Dosing</h2>
<p class="First">Dosage for Adults - one 0.5 mg capsule administered approximately one hour prior to the start of chemotherapy. ALOXI can be taken with or without food.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_abff6fc2-20a6-4b2f-b135-e774b8c3eef2"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules, 0.5 mg</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_d6471d7a-111b-48df-af25-62107057cb64"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ALOXI is contraindicated in patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any of its components.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_5cf93e6f-4906-43a7-b51d-5bb376cfc034"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8a5bb05b-3cd7-4b3a-a37e-e573b3f09ef5"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may occur in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other 5-HT<span class="Sub">3</span> receptor antagonists<span class="Bold">. </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span><br> reactions have been very rarely reported post-marketing for intravenous palonosetron: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. No <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported for oral palonosetron.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df88ea49-b445-48ae-bae3-1e09621842e7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">The development of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with 5-HT<span class="Sub">3</span> receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> occurring with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of another 5-HT<span class="Sub">3</span> receptor antagonist alone has also been reported. The majority of reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> related to 5-HT<span class="Sub">3 </span>receptor antagonist use occurred in a post-anesthesia care unit or an infusion center.</p>
<p>Symptoms associated with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may include the following combination of signs and symptoms: <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g.,<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially with concomitant use of ALOXI and other serotonergic drugs. If symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> occur, discontinue ALOXI and initiate supportive treatment. Patients should be informed of the increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially if ALOXI is used concomitantly with other serotonergic drugs [<span class="Italics">see Drug Interactions (<a href="#LINK_19a570b8-cdb7-42e4-8513-96942f183292">7</a>), Patient Counseling </span><span class="Italics">Information (<a href="#LINK_f6ad6fb8-cd7b-4bb6-ad6d-617ebc2d615d">17</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_8f40395e-3a54-48c7-8196-61408c7b1600"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1b688911-24fe-45e7-85d6-0cc943bcb7c3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical
Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In clinical trials for the prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> induced by moderately emetogenic chemotherapy, 693 adult patients received oral palonosetron in doses ranging from 0.25 mg to 0.75 mg. Following is a listing of drug related adverse reactions reported by ≥ 2% of patients from two clinical trials.</p>
<table border="0" cellpadding="0" cellspacing="0" width="517px">
<caption><span>Table 1: Adverse Reactions ≥ 2% from Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Studies</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">0.25 mg <br>(N=157)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">0.5 mg <br>(N=161)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">0.75 mg <br>(N=375)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">0.25 mg I.V. <br>(N=163)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (3.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (3.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">21 (5.6%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14 (8.6%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (0.6%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (0.6%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9 (2.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 (3.1%)</p></td>
</tr>
</tbody>
</table>
<p>The infrequently reported adverse reactions listed below, assessed by investigators as treatment-related or causality unknown/missing, occurred following administration of ALOXI Capsules to adult patients receiving concomitant cancer chemotherapy. Of these adverse events, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (incidence 1%), was the only adverse event reported at an incidence of ≥1%. In general, adverse reactions were similar between oral and I.V. formulations.</p>
<p>Blood and Lymphatic System: &lt;1%: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>Cardiovascular: &lt;1%: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, transient <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">first degree atrioventricular block</span>, second degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, QTc prolongation.</p>
<p>Hearing and Labyrinth: &lt;1%: <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span>. </p>
<p>Eye: &lt;1%: <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>.</p>
<p>Gastrointestinal System: &lt;1%: <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>General: 1%: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, &lt;1%: <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: &lt;1%: <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
<p>Liver: &lt;1%: transient, asymptomatic increases in bilirubin. </p>
<p>Nutrition: &lt;1%: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p>Musculoskeletal: &lt;1%: <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>. </p>
<p>Nervous System: &lt;1%: postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>.</p>
<p>Psychiatric: &lt;1%: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p>Respiratory System: &lt;1%: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p>Skin: &lt;1%: <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
<p>Very rare cases (&lt;1/10,000) of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported for I.V. ALOXI from post-marketing experience.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_19a570b8-cdb7-42e4-8513-96942f183292"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Palonosetron is eliminated from the body through both renal excretion and metabolic pathways with the latter mediated via multiple CYP enzymes. Further <span class="Italics">in vitro </span>studies indicated that palonosetron is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5 (CYP2C19 was not investigated) nor does it induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.</p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> (including altered mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, and neuromuscular symptoms) has been described following the concomitant use of 5-HT<span class="Sub">3</span> receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) [<span class="Italics">see Warnings and Precautions (<a href="#LINK_df88ea49-b445-48ae-bae3-1e09621842e7">5.2</a>)</span>].</p>
<p>A study in healthy volunteers involving single-dose I.V. palonosetron (0.75 mg) and steady state oral metoclopramide (10 mg four times daily) demonstrated no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>.</p>
<p>Concomitant administration of an antacid (Maalox® liquid 30 mL) had no effect on the oral absorption or pharmacokinetics of a single capsule of palonosetron 0.75 mg in healthy subjects.</p>
<p>In controlled clinical trials, ALOXI Capsules have been safely administered with chemotherapeutic agents, systemic corticosteroids, analgesics, and drugs for <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> including function <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, acid-related disorders, and<br> antiemetics/antinauseants.</p>
<p>Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_406c9b2c-c20f-4045-a675-036f9ea1d049"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_e603fb28-110b-4d21-b0f6-47ce4c495b8c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic effect</span>s</p>
<p>Pregnancy Category B. <br>Reproduction studies have been performed in rats at oral doses up to 60 mg/kg/day (921 times the recommended human oral dose based on body surface area) and rabbits at oral doses up to 60 mg/kg/day (1841 times the recommended human oral dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to palonosetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, palonosetron should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_b400f4d2-4161-477a-89ac-34d459cae0d8"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First"> Palonosetron has not been administered to patients undergoing labor and delivery, so its effects on the mother or child are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_512bfb9a-b72e-4044-be0c-0c833d4a25d4"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether palonosetron is excreted in human milk. <br> Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants and the potential for tumorigenicity shown for palonosetron in the rat carcinogenicity study, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_ec23e3d5-187d-45d1-b8e1-6be6cad6f7c1"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in patients below the age of 18 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_f56ccb9c-1451-4d16-8e84-5dc51d6e87dd"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of adult cancer patients in a pivotal study of oral palonosetron, 181 were 65 years of age and over. The number of geriatric patients receiving 0.5 mg palonosetron was insufficient to draw any efficacy or safety conclusions.</p>
<p> In a cross-study comparison, after a single oral dose (0.75 mg) the systemic exposure of palonosetron (AUC) was similar, but mean Cmax was 15% lower in healthy elderly subjects ≥65 years of age compared with the subjects &lt; 65 years of age. No dose adjustment is required for geriatric<br> patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1ef85888-bd98-4953-9f3f-0e8651abafd0"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Renal
Impairment</h2>
<p class="First">Mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> does not significantly affect palonosetron pharmacokinetic parameters. Total systemic exposure to intravenous ALOXI increased by approximately 28% in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> relative to healthy subjects. Dosage adjustment is not necessary in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The pharmacokinetics of palonosetron have not been studied in subjects with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fa39a8b0-1b82-4a65-947f-6327dc25a67b"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Hepatic
Impairment</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> does not significantly affect total body clearance of intravenous palonosetron compared to the healthy subjects. Dosage<br> adjustment is not necessary in patients with any degree of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f85c8400-71f6-4de4-829e-02c8e26176ca"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Race</h2>
<p class="First">Oral pharmacokinetics of palonosetron were characterized in thirty-two healthy Japanese male subjects using solution over the dose range of 3-90 µg/kg. The apparent total body clearance was 26% higher in Japanese males than in white males based on a cross-study comparison; however, no dose adjustment is necessary. The pharmacokinetics of palonosetron in other races have not been adequately characterized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46306743-ae1f-4fb0-a228-6bf413c4d209"></a><a name="section-8.9"></a><p></p>
<h2>8.9 Gender</h2>
<p class="First">Although a single dose of 0.5 mg ALOXI Capsule was associated with a 26- 35% higher systemic exposure in female subjects than in male subjects, dosage adjustment is not necessary based on gender.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_a59f7616-384a-40a5-adc4-bdeab862dab8"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known antidote to ALOXI. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> should be managed with supportive care.</p>
<p>Thirty-three adult cancer patients were administered oral palonosetron at a dose of 90 µg/kg (equivalent to 6 mg fixed dose) as part of a dose ranging study. This is approximately 12 times the recommended oral dose of 0.5 mg. This dose group had a similar incidence of adverse events compared to the other dose groups and no dose response effects were observed.</p>
<p>Dialysis studies have not been performed, however, due to the large volume of distribution, dialysis is unlikely to be an effective treatment for palonosetron <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. A single oral dose of palonosetron at 500 mg/kg in rats and 100 mg/kg in dogs (7673 and 5115 times the recommended human oral dose, respectively, based on body surface area) was lethal. The major signs of toxicity included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, labored breathing, and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_66ac1021-ae82-4e04-89f2-f746cd366602"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ALOXI (palonosetron HCl) Capsules is an antiemetic and antinauseant agent. It is a serotonin subtype 3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3a<span class="Underline">S)</span>-2-[(<span class="Underline">S</span>)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1<span class="Italics">H-</span>benz[<span class="Italics">de</span>]isoquinoline hydrochloride. The empirical formula is C<span class="Sub">19</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O.HCl, with a molecular weight of 332.87. Palonosetron hydrochloride exists as a single isomer and has the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd06f321-bb42-4748-92f3-d59626b540e0&amp;name=aloxi-capsules-1.jpg"></div>
<p>Palonosetron hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, soluble in propylene glycol, and slightly soluble in ethanol and 2-propanol.</p>
<p>Each light beige opaque soft gelatin ALOXI Capsule contains 0.56 mg of palonosetron HCl equivalent to palonosetron 0.5 mg. Inactive ingredients are: mono- and di-glycerides of capryl/capric acid, glycerin, polyglyceryl oleate, water, and butylated hydroxyanisole.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_107ed3b8-9a04-4cef-adbe-9ee8a66c84de"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_9f24b1dc-286a-419c-86f6-f7499420ad8b"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Palonosetron is a 5-HT<span class="Sub">3</span> receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors.</p>
<p> Cancer chemotherapy may be associated with a high incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, particularly when certain agents, such as cisplatin, are used. 5- HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT<span class="Sub">3</span> receptors located on vagal afferents to initiate the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> reflex.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_9dd7e96e-1376-44a5-80dd-11eff3a7f37c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In non-clinical studies palonosetron possesses the ability to block ion channels involved in ventricular de- and re-polarization and to prolong action potential duration.</p>
<p>The effect of palonosetron on QTc interval was evaluated in a double blind, randomized, parallel, placebo and positive (moxifloxicin) controlled trial in adult men and women. The objective was to evaluate the ECG effects of intravenously administered palonosetron at single doses of 0.25 mg, 0.75 mg or 2.25 mg in 221 healthy subjects. The study demonstrated no significant effect on any ECG interval including QTc duration (cardiac repolarization) at doses up to 2.25 mg.</p>
<p>Clinical trials revealed that oral palonosetron had comparable effects on blood pressure, heart rate, and ECG parameters as intravenous palonosetron.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_cd6f60c3-464c-4e4e-8acf-e606d0816744"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Following oral administration, palonosetron is well absorbed with its absolute bioavailability reaching 97%. After single oral doses using buffered solution mean maximum palonosetron concentrations (C<span class="Sub">max</span>) and area under the concentration-time curve (AUC<span class="Sub">0-∞</span>) were dose proportional over the dose range of 3.0 to 80 µg/kg in healthy subjects.</p>
<p>In 36 healthy male and female subjects given a single oral dose of ALOXI Capsules 0.5 mg, maximum plasma palonosetron concentration (C<span class="Sub">max</span>) was 0.81±1.66 ng/mL (mean ± SD) and time to maximum concentration (T<span class="Sub">max</span>) was 5.1± 1.7 hours. In female subjects (n=18), the mean AUC was 35% higher and the mean Cmax was 26% higher than in male subjects (n=18).</p>
<p>In 12 cancer patients given a single oral dose of palonosetron 0.5 mg one hour prior to chemotherapy, C<span class="Sub">max</span> was 0.93±0.34 ng/mL and T<span class="Sub">max</span> was 5.1± 5.9 hours. The AUC was 30% higher in cancer patients than in healthy subjects. The mean PK parameters after a single oral dose of 0.5 mg palonosetron are compared between healthy subjects and cancer patients (Table 2).</p>
<table border="0" cellpadding="0" cellspacing="0" width="539px">
<caption><span>Table 2: Mean PK Parameters<span class="Sup">1 </span>(± SD) of Palonosetron after a Single Dose of 0.5 mg ALOXI Capsules in Healthy Subjects and Cancer Patients</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">PK Parameters</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Healthy subjects <br>(n=36)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Cancer patients <br>(n=12)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">C<span class="Sub">max</span> (ng/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.81 ± 0.17</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.93 ± 0.34</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">T<span class="Sub">max </span>(h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.1 ± 1.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.1 ± 5.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">AUC<span class="Sub">∞</span> (ng·h/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">38.2 ± 11.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">49.7 ±12.2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">t<span class="Sub">1/2</span> (h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">37 ± 12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">48 ± 19</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">1</span> a cross-study comparison</p>
<p>A high fat meal did not affect the Cmax and AUC of oral palonosetron. Therefore, ALOXI Capsules may be taken without regard to meals.</p>
<p><span class="Underline">Distribution<br></span>Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg. Approximately 62% of palonosetron is bound to plasma proteins.</p>
<p><span class="Underline">Metabolism<br></span>Palonosetron is eliminated by multiple routes with approximately 50% metabolized to form two primary metabolites: N-oxide-palonosetron and 6-S- hydroxy-palonosetron. These metabolites each have less than 1% of the 5-HT<span class="Sub">3</span> receptor antagonist activity of palonosetron. <span class="Italics">In vitro </span>metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron. However, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of CYP2D6 substrates.</p>
<p><span class="Underline">Elimination<br></span>Following administration of a single oral 0.75 mg dose of [<span class="Sup">14</span>C]- palonosetron to six healthy subjects, 85% to 93% of the total radioactivity was excreted in urine, and 5% to 8% was eliminated in feces. The amount of unchanged palonosetron excreted in the urine represented approximately 40% of the administered dose. In healthy subjects given ALOXI Capsules 0.5 mg, the terminal elimination half-life (t½) of palonosetron was 37 ± 12 hours (mean ± SD), and in cancer patients, t½ was 48 ± 19 hours. After a single- dose of approximately 0.75 mg intravenous palonosetron, the total body clearance of palonosetron in healthy subjects was 160 ± 35 mL/h/kg (mean ± SD) and renal clearance was 66.5 ± 18.2 mL/h/kg.</p>
<p><span class="Underline">Special Populations</span></p>
<p><span class="Italics">[see USE IN SPECIFIC POPULATIONS (<a href="#LINK_f56ccb9c-1451-4d16-8e84-5dc51d6e87dd">8.5</a>-<a href="#LINK_46306743-ae1f-4fb0-a228-6bf413c4d209">8.9</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_1347059e-0b19-4951-978e-1ec79e765e17"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_5d9c9bae-e116-497b-ac61-eceb5d519709"></a><a name="section-12.1"></a><p></p>
<h2>13.1 

Carciogenesis,
Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 104-week carcinogenicity study in CD-1 mice, animals were treated with oral doses of palonosetron at 10, 30 and 60 mg/kg/day. Treatment with palonosetron was not tumorigenic. The highest tested dose produced a systemic exposure to palonosetron (Plasma AUC) of about 90 to 173 times the human exposure (AUC= 49.7 ng·h/mL) at the recommended oral dose of 0.5 mg. In a 104-week carcinogenicity study in Sprague-Dawley rats, male and female rats were treated with oral doses of 15, 30 and 60 mg/kg/day and 15, 45 and 90 mg/kg/day, respectively. The highest doses produced a systemic exposure to palonosetron (Plasma AUC) of 82 and 185 times the human exposure at the recommended dose. Treatment with palonosetron produced increased incidences of adrenal benign <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> and combined benign and malignant <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, increased incidences of pancreatic Islet cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and combined <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and carcinoma and <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenoma</span> in male rats. In female rats, it produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> and carcinoma and increased the incidences of thyroid C-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and combined <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> and carcinoma.</p>
<p>Palonosetron was not genotoxic in the Ames test, the Chinese hamster ovarian cell (CHO/HGPRT) forward mutation test, the <span class="Italics">ex vivo </span>hepatocyte unscheduled DNA synthesis (UDS) test or the mouse micronucleus test. It was, however, positive for clastogenic effects in the Chinese hamster ovarian (CHO) cell chromosomal aberration test.</p>
<p>Palonosetron at oral doses up to 60 mg/kg/day (about 921 times the recommended human oral dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_2c38ac0c-4830-4646-b27c-2732b5673cf0"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Study 1 was a multicenter, randomized, double-blind active control clinical trial of 635 patients set to receive moderately emetogenic cancer chemotherapy. A single-dose of 0.25 mg, 0.5 mg, or 0.75 mg oral ALOXI Capsules given one hour prior to moderately emetogenic chemotherapy was compared to a single-dose of 0.25 mg I.V. ALOXI given 30 minutes prior to chemotherapy. Patients were randomized to either dexamethasone or placebo in addition to their assigned treatment. The majority of patients in the study were women (73%), white (69%), and naïve to previous chemotherapy (59%). The primary efficacy endpoint was Complete Response (no emetic episodes and no rescue medication) assessed in the acute phase (0-24 hours). A key secondary efficacy endpoint was Complete Response assessed in the delayed phase (24-120 hours). Other secondary endpoints included Complete Response for the acute plus delayed phases (0-120 hours) and No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> for the acute and delayed phases.</p>
<p>Efficacy was based on demonstrating non-inferiority of oral palonosetron doses compared to the approved I.V. formulation. Non- inferiority criteria were met if the lower bound of the two-sided 98.3% confidence interval for the difference in complete response rates of oral palonosetron dose minus approved I.V. formulation was larger than -15%. The non-inferiority margin was 15%.</p>
<p><span class="Underline">Efficacy Results<br></span>As shown in Table 3, ALOXI Capsules 0.5 mg demonstrated non- inferiority to the active comparator during the 0 to 24 hour time interval; however, for the 24 to 120 hour time period, non-inferiority was not shown. The additional two oral palonosetron dose levels showed similar results.</p>
<table cellpadding="0" cellspacing="0" width="576px">
<caption><span>Table 3: Proportion of Patients Achieving Complete Response Post- Chemotherapy</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Time Period</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Oral<br>ALOXI<br>0.5 mg<br> (N=160)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">I.V.<br>ALOXI<br>0.25 mg <br>(N=162)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Difference [Two-sided 98.3%<br>Confidence Interval]*: Oral <br>ALOXI minus I.V. ALOXI<br>Comparator</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0-24 hr</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">76.3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">70.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9% [-6.5%<span class="Bold">, </span>18.2%]</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">24-120 hr</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">62.5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">65.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-2.9% [-16.3%, 10.5%]</p></td>
</tr>
</tbody>
</table>
<p>*To adjust for multiplicity of treatment groups, a lower-bound of a two-sided 98.3% confidence interval was used to compare to -15%, the negative value of the non-inferiority margin.</p>
<p>As indicated in the data above, analysis of the key secondary endpoint showed that a single dose of ALOXI Capsules 0.5 mg was numerically similar to a single dose of I.V. ALOXI 0.25 mg, however, statistical non-inferiority was not demonstrated. For ALOXI Capsules 0.5 mg versus I.V. ALOXI 0.25 mg, the proportion of patients with complete response at 0-120 hours was 58.8% versus 59.3%, respectively. The proportions of patients with no <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> at 0-24 and 24-120 hours were also numerically similar between oral and I.V. doses.</p>
<p>Study 2 was a multicenter, open label, repeat cycle study performed to evaluate the safety and efficacy of single dose oral ALOXI Capsules 0.75 mg in cancer patients receiving moderately emetogenic chemotherapy. An ALOXI Capsule was given to 217 cancer patients in 654 chemotherapy cycles one hour before the start of chemotherapy. Approximately 74% of patients also received single dose oral or intravenous dexamethasone 30 minutes before chemotherapy. Complete Response was not formally evaluated for the repeat cycle application. However, in general the antiemetic effect for the 0-24 hour interval was similar throughout the consecutively repeated cycles.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_cf9b015e-3f82-4242-ba30-6fc80a47a4e2"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC #62856-799-05, ALOXI Capsules, 0.5 mg (free base), are supplied as light beige opaque soft gelatin capsules, five capsules per bottle, each bottle packaged in a small carton.</p>
<p><span class="Bold">Storage</span></p>
<ul class="Disc">
<li>Store at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [see USP Controlled Room Temperature].</li>
<li>Protect from light.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_f6ad6fb8-cd7b-4bb6-ad6d-617ebc2d615d"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labelling (Patient Information).</p>
<p><span class="Bold">Instructions for Patients</span></p>
<p>Advise patients  of the possibility of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, especially with concomitant use of ALOXI and another serotonergic agent such as medications to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>.  Advise patients  to seek immediate medical attention if the following symptoms occur: changes in mental status, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>, neuromuscular symptoms  with or without gastrointestinal symptoms  [<span class="Italics">see Warnings and Precautions (<a href="#LINK_df88ea49-b445-48ae-bae3-1e09621842e7">5.2</a>)</span>].</p>
<p>Patients should be instructed to read the Patient Information.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_7a4379b6-5684-49c5-96e6-bf035619dedc"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">ALOXI</span><span class="Bold">® </span>(Ah-lock-see)</p>
<p>(palonosetron HCl)</p>
<p>Capsules</p>
<p>Read the Patient Information that comes with ALOXI before you start taking it and each time you refill your prescription. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">Wha</span><span class="Bold">t is ALOXI?</span></p>
<p>ALOXI is a prescription medicine used in adults to help prevent the <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that happens with certain anti-cancer medicines (chemotherapy).</p>
<p>It is not known if ALOXI is safe and effective in people under the age of 18 years.</p>
<p><span class="Bold">Who should not take ALOXI?</span></p>
<p><span class="Bold">Do not take ALOXI if you are allergic to any of the ingredients in ALOXI. </span>See the end of this leaflet for a complete list of ingredients in ALOXI.</p>
<p><span class="Bold">What should I tell my doctor before taking ALOXI?</span></p>
<p>Tell your doctor about all of your medical conditions, including if you:</p>
<ul class="Disc">
<li>have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to another medicine for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, such as Kytril (granisetron), Anzemet (dolasetron), Zofran (ondansetron), or to the medicine Lotronex (alosetron).</li>
<li>
<span class="Bold">ar</span><span class="Bold">e pregnant</span>. It is not known if ALOXI may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li>
<li>
<span class="Bold">are breast-feeding or plan to breast-feed</span>. It is not known if ALOXI passes into your milk. You and your doctor should decide if you will take ALOXI or breast-feed.</li>
</ul>
<p>You should not do both.</p>
<p><span class="Bold">How should I take ALOXI?</span></p>
<ul class="Disc">
<li>Take ALOXI exactly as prescribed by your doctor.</li>
<li>Take one ALOXI Capsule by mouth about one hour before you get your anti-cancer medicine (chemotherapy).</li>
<li>ALOXI can be taken with or without food.</li>
<li>If you take too much ALOXI, tell your doctor right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ALOXI?</span></p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> can happen with ALOXI. Tell your doctor if you experience <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the skin, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</p>
<p>The most common side effects of ALOXI are:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> (<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>)</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. <br> These are not all the possible side effects of ALOXI. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1- 800-FDA-1088.</p>
<p><span class="Bold">How should I store ALOXI?</span></p>
<ul class="Disc">
<li>Store ALOXI at 59°F to 86°F (15°C to 30°C).</li>
<li>Keep ALOXI away from light.</li>
</ul>
<p><span class="Bold">Keep ALOXI out of the reach of children.</span></p>
<p><span class="Bold">General information about ALOXI</span></p>
<p>Medicines are sometimes prescribed for conditions other than those listed in patient information leaflets. Do not take ALOXI for a condition for which it was not prescribed. Do not give ALOXI to other people even if they have the same condition that you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about ALOXI. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ALOXI that is written for health professionals. For more information call 1-888-422-4743, or go to www.ALOXI.com.</p>
<p><span class="Bold">What are the ingredients in ALOXI?</span></p>
<p>Active ingredient: palonosetron hydrochloride</p>
<p>Inactive ingredients: Mono-glycerides and di-glycerides of capryl/capric acid, glycerin, polyglyceryl oleate, water, and butylate hydroxyanisole</p>
<p>Jointly manufactured by Catalent Pharma Solutions, Somerset NJ and Philadelphia PA, USA, and Helsinn Birex Pharmaceuticals, Dublin, Ireland</p>
<p>HELSINN, Manufactured for Helsinn Healthcare SA, Switzerland</p>
<p>Distributed and marketed by Eisai Inc., Woodcliff Lake, NJ 07677</p>
<p>ALOXI<span class="Sup">®</span> is a registered trademark of Helsinn Healthcare SA, Lugano, Switzerland</p>
<p>©2014 Eisai Inc., US Patent No. 5.202.333 </p>
<p>Revised 09/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_88314d79-8466-4455-9670-37fd682d583c"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Principal Display Panel</span><br>NDC 62856-799-05<br>Aloxi<br>palonosetron HCI capsules<br>0.5 mg<br>5 capsules</p>
<div class="Figure"><img alt="NDC 62856-799-05 Aloxi palonosetron HCI capsules 0.5 mg 5 capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd06f321-bb42-4748-92f3-d59626b540e0&amp;name=aloxi-capsules-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALOXI 		
					</strong><br><span class="contentTableReg">palonosetron hydrochloride capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62856-799</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PALONOSETRON HYDROCHLORIDE</strong> (PALONOSETRON) </td>
<td class="formItem">PALONOSETRON</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CAPRYLIC/CAPRIC MONO/DIGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYGLYCERYL-3 DIOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (light beige opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">3mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AIO</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62856-799-05</td>
<td class="formItem">5  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022233</td>
<td class="formItem">08/22/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Eisai Inc.
							(831600833)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3b51614c-4d17-4635-980e-f9edb278ff9d</div>
<div>Set id: bd06f321-bb42-4748-92f3-d59626b540e0</div>
<div>Version: 4</div>
<div>Effective Time: 20140930</div>
</div>
</div> <div class="DistributorName">Eisai Inc.</div></p>
</body></html>
